Evidence map›Paper›PMID 23649020›Full record

ReviewNature reviews. Nephrology2013

Three feasible strategies to minimize kidney injury in 'incipient AKI'.

Mark A Perazella, Steven G Coca

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. An HRedox biology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Taboo in cardiology: renin-angiotensin-aldosterone system antagonists worsening renal failure.European heart journal supplements : journal of the European Society of Cardiology · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. "I don't get no respect": the role of chloride in acute kidney injury.American journal of physiology. Renal physiology · 2019
    Review
  19. Acute kidney injury and 'nephrotoxins': mind your language.Clinical medicine (London, England) · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mark A PerazellaYale University School of Medicine, Section of Nephrology, 330 Cedar Street, New Haven, CT 06520, USA.
Steven G Coca

Funding

Progression of Acute Kidney Injury to Chronic Kidney DiseaseU01DK082185 · NIDDK · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2008 to 2017
$5.1M
Novel serum and urinary biomarkers of diabetic kidney diseaseR01DK096549 · NIDDK · YALE UNIVERSITY · PI COCA, STEVEN G · 2012 to 2016
$2.9M
Long-term Prognosis of Acute Kidney Injury in Cardiac SurgeryK23DK080132 · NIDDK · YALE UNIVERSITY · PI COCA, STEVEN G · 2008 to 2012
$957k
NIDDK NIH HHS K23DK080132NIDDK NIH HHS R01DK096549NIDDK NIH HHS U01DK082185
6 · The paper itself

Abstract

Acute kidney injury (AKI) is common and increasing in hospitalized patients. The earlier recognition of renal injury, at a stage described as 'incipient AKI', may allow renoprotective strategies to be initiated at a time when more kidney tissue is salvageable. 'Incipient AKI' represents renal injury as manifested by new-onset proteinuria, cellular activity on urine microscopy, or elevated novel biomarkers of kidney injury in the absence of clinical data that meet current diagnostic criteria for AKI. We propose three strategies to preserve kidney function and minimize further kidney injury in patients with 'incipient AKI'. These include--when appropriate for the prevailing cause of 'incipient AKI'--use of low-chloride-containing intravenous solutions, continued use of renin-angiotensin system antagonists, and use of diuretics to achieve adequate control of intravascular volume. The combined approach of the early diagnosis of AKI and early employment of feasible therapeutic strategies may slow the growth of clinical AKI, AKI requiring renal replacement therapy and chronic kidney disease, and might reduce AKI-associated mortality.

Indexed as

Acute Kidney InjuryAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsDiureticsFluid TherapyHumansIsotonic SolutionsKidney Failure, ChronicRenal Insufficiency, ChronicRenin-Angiotensin SystemAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsDiureticsIsotonic Solutions

Identifiers

PMID23649020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.